Radiopharm advances to Cohort 3 in cancer trial
Radiopharm Theranostics (ASX:RAD) reached a clinical milestone following a positive recommendation from the Data Safety and Monitoring Committee.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Radiopharm Theranostics (ASX:RAD) reached a clinical milestone following a positive recommendation from the Data Safety and Monitoring Committee.
TOMI Environmental Solutions (NASDAQ:TOMZ), a global provider of disinfection and decontamination essentials, announced preliminary unaudited financial results for the first quarter of 2026 on April 8, highlighting a 67% sequential revenue increase over the fourth quarter of 2025.
Atkore (NYSE:ATKR) announced on April 8, 2026, the sale of its High-Density Polyethylene (HDPE) pipe and conduit business to Infra Pipes, a prominent North American manufacturer of polyethylene pipeline solutions.
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, announced on April 8, 2026, that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to REYOBIQ™ (rhenium Re186 obisbemeda).
RPM International (NYSE:RPM) reported record financial results for its fiscal 2026 third quarter ended February 28, 2026, characterized by robust top-line growth and a significant expansion in operating margins across its global specialty coatings and building materials portfolio.
Pony.ai (NASDAQ:PONY), a global leader in autonomous driving technology, reached a historic milestone on April 8, 2026, with the launch of Europe’s first commercial robotaxi service in Zagreb, Croatia.
New academic research suggests that a quantum attack capable of overtaking Bitcoin mining would require hardware and energy on a scale comparable to a star, placing it far beyond physical feasibility.
Hemispherian, a clinical-stage oncology company, announced on April 8, 2026, the initiation of a Phase 1/2a clinical trial for its lead candidate, GLIX1, marking a significant milestone in the development of targeted therapies for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.
The Australian Financial Services Licence will initially allow the exchange to offer crypto and equity perpetuals, with plans to add futures, options and payments services.
Binance said it will introduce a new spot trading mechanism on April 14 to restrict order execution outside a defined price range during periods of high volatility.